Search
Dermata Therapeutics Inc
DRMAAdd to Watchlist
1.150USD
0.0000.00%
Market hours 09/22, 15:47（ET）
4.62MMarket Cap
LossP/E TTM
Dermata Therapeutics Inc (DRMA) Stock Price Target & Forecast
Analyst Rating
Based on 1 analysts giving stock ratings to Dermata Therapeutics Inc in the past month.
Buy
0 Strong Buy
1 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
4.000USD+244.83%
DRMA Analyst Recommendation Trends
In the current month, DRMA has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DRMA average Analyst price target in the last month is 4.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
Financial Forecasting
Based on analysts' estimates, DRMA EPS is projected to reach -0.550 in FY2026Q3, following reported EPS of -0.738 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.54
-0.53
-0.55
-0.55
-0.46
Actual
-1.65
-0.48
-0.74
--
--
Surprise
-6.92%
+9.66%
-34.12%
--
--
FAQs
What is Dermata Therapeutics Inc's price target?
Analysts forecast that Dermata Therapeutics Inc's price target is USD 10.00, with the highest forecast at USD 10.00 and the lowest forecast at USD 10.00.
How have Dermata Therapeutics IncDRMA's recent earnings per share performed?
The market expectation was USD -0.74, while Dermata Therapeutics IncDRMA's earnings per share (EPS) for the previous quarter was USD -0.48. EPS for the next quarter is expected at USD -0.55.
What is the analyst rating for Dermata Therapeutics Inc?
Based on the ratings of Dermata Therapeutics Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.